Conference Reports

Singapore
13 July 2017 - 15 July 2017
San Diego, California, US
09 June 2017 - 13 June 2017
Washington, DC
19 May 2017 - 24 May 2017
Houston, Texas, US
22 February 2017 - 24 February 2017
12 November 2016 - 16 November 2016
Yangon
14 October 2016 - 16 October 2016
Rome
27 August 2016 - 31 August 2016
Mexico City
04 June 2016 - 07 June 2016
New Orleans, Louisiana
10 June 2016 - 14 June 2016
London
29 August 2015 - 02 September 2015
Barcelona
30 August 2014 - 09 September 2014
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 24 Jun 2015
Adding sitagliptin, a dipeptidyl peptidase 4 inhibitor (DPP-4), to usual care in patients with glycaemic equipoise does not increase the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), according to the TECOS* study.
Christina Lau, 15 Jun 2016
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant reductions in major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular (CV) risk in the LEADER (Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcomes Results) trial.
Elvira Manzano, 21 Nov 2016
Newer metabolic agents, including trimetazidine, represent ancillary forms of prophylactic antianginal therapy and may be useful in patients with stable coronary artery disease (SCAD) who are unsuitable for percutaneous or surgical revascularization, says a leading cardiologist at the recent AFCC 2016.
Pearl Toh, 14 Jun 2016
Cardiovascular magnetic resonance (CMR) is a stronger predictor of major adverse cardiovascular events (MACE) compared with single-photon emission computed tomography (SPECT), according to the CE-MARC* study.